Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated August 26, 2024, reports on the company's ongoing share repurchase programme. Novo Nordisk is a leading global healthcare company headquartered in Denmark, employing approximately 69,000 people across 80 countries. The filing details transactions executed under a specific sub-programme initiated on August 7, 2024, which is part of a broader 12-month repurchase plan authorized to begin on February 6, 2024.
Key Financial Metrics
The filing focuses exclusively on capital allocation activities regarding share buybacks and does not report operational financial metrics such as revenue, profit, cash flow, margins, or debt levels.
- Total Repurchase Programme Cap: Up to DKK 20 billion.
- Specific Sub-Programme (Aug 7 - Nov 4, 2024): Up to DKK 2.4 billion.
- Accumulated Repurchases (Feb 6 - Aug 23, 2024): 11,607,313 B shares.
- Accumulated Transaction Value (Feb 6 - Aug 23, 2024): DKK 10,213,705,118.
- Average Share Price (Feb 6 - Aug 23, 2024): DKK 879.94 per B share.
- Treasury Shares Held: 12,935,944 B shares (0.3% of share capital).
Material Changes
Since the previous announcement on August 19, 2024, the company executed daily repurchases of 41,000 B shares from August 20 through August 23, 2024. The average purchase price for these specific transactions ranged between DKK 908.38 and DKK 919.59. The total accumulated transaction value under the specific August 7 programme reached DKK 485,999,068 as of August 23, 2024.
Guidance, Outlook, and Risks
Novo Nordisk expects to continue repurchasing B shares up to the total programme limit of DKK 20 billion during the 12-month period starting February 6, 2024. The company operates under the "Safe Harbour Rules" of the European Union (MAR and Commission Delegated Regulation). The filing does not provide specific operational guidance, risk factors, or commentary on future earnings, as the document is strictly a disclosure of share repurchase activity.
Investor Verification Checklist
- Verify the total remaining capacity under the DKK 20 billion programme (approximately DKK 9.79 billion remaining as of August 23).
- Confirm the current market price of Novo Nordisk B shares relative to the recent average repurchase price of DKK 879.94.
- Review the company's latest Form 20-F or quarterly reports for operational financial performance, as this 6-K does not contain revenue or profit data.
- Monitor the end date of the current sub-programme (November 4, 2024) for potential acceleration or cessation of buybacks.